Cerus CERS Stock
Cerus Price Chart
Cerus CERS Financial and Trading Overview
| Cerus stock price | 1.85 USD |
| Previous Close | 1.9 USD |
| Open | 1.84 USD |
| Bid | 2.09 USD x 200 |
| Ask | 2.76 USD x 200 |
| Day's Range | 1.82 - 1.95 USD |
| 52 Week Range | 1.47 - 3.47 USD |
| Volume | 4.51M USD |
| Avg. Volume | 2.09M USD |
| Market Cap | 373.62M USD |
| Beta (5Y Monthly) | 1.853 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.04 USD |
| Forward Dividend & Yield | N/A (0%) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.13 USD |
CERS Valuation Measures
| Enterprise Value | 392.13M USD |
| Trailing P/E | N/A |
| Forward P/E | 123.333336 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 1.6490275 |
| Price/Book (mrq) | 4.9333334 |
| Enterprise Value/Revenue | 1.731 |
| Enterprise Value/EBITDA | -524.234 |
Trading Information
Cerus Stock Price History
| Beta (5Y Monthly) | 1.853 |
| 52-Week Change | 17.28% |
| S&P500 52-Week Change | 8.67% |
| 52 Week High | 3.47 USD |
| 52 Week Low | 1.47 USD |
| 50-Day Moving Average | 2.31 USD |
| 200-Day Moving Average | 2.42 USD |
CERS Share Statistics
| Avg. Volume (3 month) | 2.09M USD |
| Avg. Daily Volume (10-Days) | 3.66M USD |
| Shares Outstanding | 201.95M |
| Float | 195.78M |
| Short Ratio | 8.08 |
| % Held by Insiders | 3.60% |
| % Held by Institutions | 76.01% |
| Shares Short | 14.63M |
| Short % of Float | 7.45% |
| Short % of Shares Outstanding | 7.24% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | September 30, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | -3.22% |
| Operating Margin (ttm) | -1.090% |
| Gross Margin | 51.83% |
| EBITDA Margin | -0.33% |
Management Effectiveness
| Return on Assets (ttm) | -0.73% |
| Return on Equity (ttm) | -10.67% |
Income Statement
| Revenue (ttm) | 226.57M USD |
| Revenue Per Share (ttm) | 1.15 USD |
| Quarterly Revenue Growth (yoy) | 9.50% |
| Gross Profit (ttm) | 117.44M USD |
| EBITDA | -748000 USD |
| Net Income Avi to Common (ttm) | -7314000 USD |
| Diluted EPS (ttm) | -0.04 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 57.11M USD |
| Total Cash Per Share (mrq) | 0.28 USD |
| Total Debt (mrq) | 74.96M USD |
| Total Debt/Equity (mrq) | 98.16 USD |
| Current Ratio (mrq) | 1.957 |
| Book Value Per Share (mrq) | 0.375 |
Cash Flow Statement
| Operating Cash Flow (ttm) | 3.5M USD |
| Levered Free Cash Flow (ttm) | 2.13M USD |
Profile of Cerus
| Country | United States |
| State | CA |
| City | Concord |
| Address | 1220 Concord Avenue |
| ZIP | 94520 |
| Phone | 925 288 6000 |
| Website | https://www.cerus.com |
| Industry | Medical Devices |
| Sector(s) | Healthcare |
| Full Time Employees | 261 |
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The company offers INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company also offers INTERCEPT Blood Systems for platelets plasma, and cryoprecipitation, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells intended for transfusion; INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma and cryoprecipitate reduced; and INTERCEPT Illuminator, an LED-based device for blood component treatment. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was formerly known as CERUS TECHNOLOGIES INC and changed its name to Cerus Corporation in July 1996. The company was incorporated in 1991 and is headquartered in Concord, California.
Q&A For Cerus Stock
What is a current CERS stock price?
Cerus CERS stock price today per share is 1.85 USD.
How to purchase Cerus stock?
You can buy CERS shares on the Tech Market Middle exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Cerus?
The stock symbol or ticker of Cerus is CERS.
Which industry does the Cerus company belong to?
The Cerus industry is Medical Devices.
How many shares does Cerus have in circulation?
The max supply of Cerus shares is 201.95M.
What is Cerus Price to Earnings Ratio (PE Ratio)?
Cerus PE Ratio is now.
What was Cerus earnings per share over the trailing 12 months (TTM)?
Cerus EPS is -0.04 USD over the trailing 12 months.
Which sector does the Cerus company belong to?
The Cerus sector is Healthcare.
Cerus CERS included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
|
- | |||||
US Tech Composite
IXIC
US
|
22617.73 USD — |
-5.28
|
10.6B USD — | 22513.01 USD — | 23837.76 USD — | — - | 10.6B USD — |
US Tech Global Market Composite
NQGM
US
|
1743.91 USD — |
-3.66
|
— — | 1738.23 USD — | 1808.43 USD — | — - | — — |
US Tech Health Care
IXHC
US
|
1282.67 USD — |
-1.79
|
— — | 1279.99 USD — | 1317.94 USD — | — - | — — |
US Tech Composite Total Return
XCMP
US
|
27958.09 USD — |
-5.28
|
— — | 27828.65 USD — | 29466.09 USD — | — - | — — |
US Tech Biotechnology Total Retu
XNBI
US
|
7414.87 USD — |
-1.68
|
— — | 7398.95 USD — | 7631.86 USD — | — - | — — |


